open-label, multicenter GW572016 trastuzumab in sufferers with metastatic breast cancer. Proc Amer Soc Clin Onc. 2004, 22 3006th Blackwell KL, Burstein H, M Pegram, Storniolo A, Salazar VM, Maleski JE, Lin X, Spector N, Stein SH, Berger MS. Refractory establish Pomalidomide clinical trial biomarkers related tissues and serum response to lapatinib monotherapy Ren Ren trastuzumab breast cancer can predict metastasis. Proc Amer Soc Clin Onc. 2006, 23 # 3004th Bookman MA, Darcy KM, Clarke Pearson D, Boothby RA, Horowitz IR. Assessment Entire body humanized monoclonal directed against HER2, trastuzumab, in individuals with relapsed or refractory ovarian cancer Rer Ren or Webpage 13 Moasser Oncogene. Author manuscript 6th, April 2011 PMC. Ren Ren key peritoneal carcinoma with overexpression of HER2: a phase II study on the Gynecologic Oncology Group.
AZD1152-HQPA J Clin Oncol. 2003, 21:283 290th Bose S, Crane A. Hibshoosh H Mansukhani M, L sand Weis, R. Parsons diminished PTEN correlates with breast cancer progression Hum Pathol. 2002, 33:405 409th Ravanel FX Brand N, Gauchez AS, Pasquier D, Payan R, Fagret D, et al. Point of view of an anti-HER2 receptor in breast cancer. Anticancer Res 2006, 26:463 470th Brandt R, Wong AM, Hynes NE. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells give a novel orthotopic tumor model for testing anti-cancer agents. Oncogene. 2001, 20:5459 5465th Burstein H, Storniolo A, S Franco, Salazar VM, MS Sorenson, Stein SH. A phase II, open-label, multicenter lapatinib in two cohorts of clients with superior breast cancer or metastatic advanced to w When obtaining trastuzumab-containing regimen.
Annals of Oncology. 2004, 15 Suppl 3:27. Burstein HJ, Harris LN, Marcom PK, Lambert F Tthe R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy in HER2 overexpressing metastatic multicenter Phase II clinical benefits, the examination of serum tumor markers as pr Predictive factors, and cardiac surveillance algorithm pr. J Clin Oncol. 2003, 21:2889 2895th Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, et al. Multicentric, randomized phase II trial of CI-1033 for oral cancer previously treated sophisticated ovarian cancer. J Clin Oncol. 2005, 23:5597 5604th Carson WE, Parihar R, Lindemann MJ, Personeni N, Heath J Dierk, Meropol NJ, et al. Interleukin two enhances organic killer cell response to Herceptin for HER2/neu optimistic cells and breast cancer.
EUR J Immunol. 2001, 31:3016 3025th Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization treat an outdated RPers antip185HER2 cancer in human beings. Proc Natl Acad Sci U.S. A. 1992 89:4285 4289th Chazin VR, Kaleko M, Miller AD, Slamon DJ. Mediated transformation genes independently Ngig-gated human rights organizations HER 2 receptor of epidermal development element. Oncogene. 1992, Hung 1866 seven:1859. Chen JS, Lan K, MC. Approaches for HER2/neu overexpression for cancer targeting. Drug Resist Updat. 2003, six:129 136th Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. Construction of your extracellular Ren area of HER2 alone or complexed with Herceptin Fab Ren. Nature. 2003, 421:756 760th Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, et al. SiRNA inhibits expression in the Her2/neu ge